ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Continuing an acquisition spree, Eli Lilly and Company has snapped up its diabetes collaborator Sigilon Therapeutics and the antibody-drug conjugate company Emergence Therapeutics. The pharmaceutical giant will pay as much as $310 million for Sigilon and up to $12 million to the founding investors for Emergence. A week prior, Lilly agreed to buy the small-molecule-focused start-up Dice Therapeutics in a multibillion-dollar deal.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X